• Leukemias, lymphomas, and other hematologic cancers

Scemblix Generic Name & Formulations

General Description

Asciminib 20mg, 40mg; tabs.

Pharmacological Class

Kinase inhibitor.

How Supplied

Tabs 20mg, 40mg—60; 40mg—300 (5x60)

Generic Availability


Mechanism of Action

Asciminib inhibits the ABL1 kinase activity of the BCR-ABL1 fusion protein, by binding to the ABL myristoyl pocket. In studies conducted in vitro or in animal models of CML, asciminib showed activity against wild-type BCR-ABL1 and several mutant forms of the kinase, including the T315I mutation.

Scemblix Indications


In adults with: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with ≥2 tyrosine kinase inhibitors (TKIs); or Ph+ CML in CP with the T315I mutation.

Scemblix Dosage and Administration


Swallow whole. Take on an empty stomach. Avoid food for at least 2hrs before and 1hr after dosing. Previously treated with ≥2 TKIs: 80mg once daily (at same time each day) or 40mg twice daily (at approx. 12hr intervals). With T315I mutation: 200mg twice daily (at approx. 12hr intervals). Dose modifications for adverse reactions: see full labeling.


Not established.

Scemblix Contraindications

Not Applicable

Scemblix Boxed Warnings

Not Applicable

Scemblix Warnings/Precautions


Monitor for myelosuppression, pancreatic toxicity (increase monitoring if history of pancreatitis), hypertension, hypersensitivity. Monitor for cardiovascular signs/symptoms in those with a history of cardiovascular risk factors. Reduce dose, temporarily withhold, or permanently discontinue based on severity of adverse reactions; see full labeling. Perform CBCs every 2 weeks for the 1st 3 months, then monthly thereafter or as clinically indicated. Assess serum lipase and amylase levels monthly during therapy, or as clinically indicated; temporarily withhold if lipase and amylase elevation are accompanied by abdominal symptoms. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Scemblix Pharmacokinetics


Median Tmax of asciminib: 2.5 hours (range: 2–3 hours). 


Plasma protein bound: 97%.

Apprarent volume of distribution at steady state: 151 L.


CYP3A4-mediated oxidation, UGT2B7- and UGT2B17-mediated glucuronidation. 


Fecal (80%), renal (11%). Half-life: 5.5 hours (80mg/day); 9 hours (400mg/day).

Scemblix Interactions


Potentiated by strong CYP3A4 inhibitors (eg, clarithromycin); monitor closely. Antagonized by itraconazole oral soln containing hydroxypropyl-β-cyclodextrin; avoid. Potentiates certain CYP3A4 substrates (eg, midazolam); avoid concomitant with Scemblix at 200mg twice daily; monitor closely with Scemblix at 80mg daily dose. Potentiates CYP2C9 substrates (eg, warfarin). Avoid concomitant with certain CYP2C9 substrates at Scemblix 80mg daily dose; if unavoidable, reduce CYP2C9 substrate dose. Avoid concomitant with sensitive or certain CYP2C9 substrates at Scemblix 200mg twice daily dose; if unavoidable, consider alternatives (eg, non-CYP2C9 substrate). Potentiates P-gp substrates; monitor closely.

Scemblix Adverse Reactions

Adverse Reactions

Upper respiratory tract infections, musculoskeletal pain, headache, fatigue, nausea, rash, diarrhea, lab abnormalities (decreased platelet count, decreased neutrophil count, decreased hemoglobin, decreased lymphocyte count, increased triglycerides, increased creatine kinase, increased ALT/AST, increased lipase, increased amylase, increased uric acid); hypertension, myelosuppression, pancreatic, or cardiovascular toxicity.

Scemblix Clinical Trials

See Literature

Scemblix Note

Not Applicable

Scemblix Patient Counseling

See Literature